Edible Bird’s Nest Regulates Hepatic Cholesterol Metabolism through Transcriptional Regulation of Cholesterol Related Genes

• Published in: Evidence-based complementary and alternative medicine 2022-06, Vol.2022, p.1-10
• Main Authors: Yida, Zhang, Al-Shuwayah, Hussah, Ismail, Maznah, Imam, Mustapha Umar
• Format: Article
• Language: English
• Subjects: Biotechnology; Cardiovascular diseases; Cholesterol; Cholic acid; Creatinine; Data analysis; Enzymes; Food; Gene expression; Gene regulation; High cholesterol diet; High density lipoprotein; Hypercholesterolemia; Lipase; Lipid metabolism; Lipids; Lipoproteins; Liver; Metabolism; Risk factors; Serum lipids; Side effects; Simvastatin; Software; Uric acid; Variance analysis
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2022/8882993

Objective. Hypercholesterolemia is a strong risk factor for cardiovascular diseases. Side effects associated with the use of pharmaceutical agents can cancel out their benefits. Dietary management of hypercholesterolemia is, therefore, receiving much attention due to fewer side effects. In this study, we explored the effectiveness of edible bird’s nest (EBN) in the prevention of hypercholesterolemia in rats. Methods. High-cholesterol diet (HCD) (4.5% cholesterol and 0.5% cholic acid) with or without EBN (low (2.5%) or high dose (20%)) was given to rats for 12 weeks, and their weights were observed. Simvastatin (10 mg/kg/day) was administered for the same period as a control drug. Serum and tissue samples were collected at the end of the study, from which biochemical parameters (lipid profiles, oxLDL, liver enzymes, urea, creatinine, uric acid, and lipase activity) and hepatic mRNA levels were measured. Results. The HCD group had higher levels of serum lipids, liver enzymes, uric acid, urea, and lipase activity compared with those of the other groups. The hepatic mRNA levels of cholesterol metabolism genes (APOB, PCSK9, HMGCR, LDLR, and CYP7A1) in the HCD group also tended toward increased cholesterol production and reduced cholesterol clearance. EBN, especially the highest dose, attenuated the HCD-induced changes, partly through improving the transcriptional regulation of hepatic cholesterol metabolism genes with fold changes of 0.7, 0.6, 0.5, 1.7, and 2.7, respectively, in comparison to the HCD group. In fact, EBN produced better results than simvastatin. Conclusion. Thus, the results suggest that EBN can regulate cholesterol metabolism and, therefore, be a source of functional ingredients for the management of hypercholesterolemia.